This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- Johnson & Johnson cannot recommend any practices, procedures, or dosage administration techniques that deviate from the approved product labeling.
- ERLEADA 60 mg is not commercially available as a solution or suspension.
- For patients with a feeding tube, ERLEADA 60 mg tablets can be administered through a feeding tube 8 French or greater.1
ALTERNATE METHOD OF ADMINISTRATION
Administer 60 mg Tablets Through a Feeding Tube
ERLEADA 60 mg tablets (prescribed dose of 240 mg, 180 mg, or 120 mg) can be administered through a feeding tube 8 French or greater as follows1:
- Place the entire prescribed dose of ERLEADA tablets in the barrel of the syringe (use at least a 50 mL syringe) and draw up 20 mL of non-carbonated water into the syringe.
- Wait 10 minutes and then shake vigorously to disperse contents completely.
- Administer immediately through the feeding tube.
- Refill the syringe with non-carbonated water and administer. Repeat until no tablet residue is left in the syringe or feeding tube.
Literature Search
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 10 July 2024.
1 | Data on File. Apalutamide. Company Core Data Sheet. Janssen Research & Development, LLC. EDMS-ERI-146013831; 2024. |